SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-097497
Filing Date
2022-04-06
Accepted
2022-04-06 16:20:03
Documents
12
Period of Report
2022-04-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d345665d8k.htm   iXBRL 8-K 24592
  Complete submission text file 0001193125-22-097497.txt   150024

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA labp-20220405.xsd EX-101.SCH 2869
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE labp-20220405_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE labp-20220405_pre.xml EX-101.PRE 11716
6 EXTRACTED XBRL INSTANCE DOCUMENT d345665d8k_htm.xml XML 3466
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 22810777
SIC: 2834 Pharmaceutical Preparations